BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AbbVie (ABBV) Seeks to Block Release of Clinical Trial Data


3/11/2013 7:21:19 AM

AbbVie Inc. (ABBV), the drugmaker that was split off from Abbott Laboratories (ABT) at the start of this year, sued the European Union’s pharmaceuticals regulator in a bid to block publication of clinical-trial data. AbbVie, based in North Chicago, Illinois, filed two lawsuits against the European Medicines Agency at the European Union General Court in Luxembourg “seeking to protect AbbVie’s confidential and commercially sensitive information,” the company said in an e-mailed statement today. The EU regulator promised in 2010 to bolster its transparency by disclosing -- on demand -- clinical trial data for every drug reviewed. Drug safety activists pressed for the move amid concerns over suicide risks linked to Sanofi (SAN)’s failed diet pill Acomplia. AbbVie said while it supports transparency of clinical research and safety information “for the benefit of patients and healthcare professionals,” it opposes the publication of information “that does not meaningfully contribute to the scientific review or evaluation of our products.” EMA representatives didn’t immediately return a call and e- mail seeking comment.


AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES